Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CWP232291 Dose-Finding Study in Relapsed/Refractory Myeloma
NCT02426723Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of CWP232291 in multiple myeloma (MM) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Recommended dose of Phase 2 trial of CWP232291 up to 4 weeks. Started Oct 2015; status: completed.
02
Drugs
CWP232291
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02426723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426723.